Related Experiment Video
Updated: Jun 27, 2025

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
Published on: July 12, 2021
Association between Genetic Polymorphism of SCN1A, GABRA1 and ABCB1 and Drug Responsiveness in Vietnamese Epileptic
Hai Xuan Tang1, Muoi Dang Ho1, Nhung Phuong Vu2
1Nghe An Obstetrics and Pediatrics Hospital, 19 Ton That Tung, Vinh 460000, Nghe An, Vietnam.
Insights
Genetic variations in the SCN1A gene are linked to drug-resistant epilepsy in Vietnamese children. Specific SCN1A polymorphisms increase the risk of refractory epilepsy, impacting treatment outcomes.
Area of Science:
- Genetics
- Neurology
- Pharmacogenomics
Background:
- Drug-resistant epilepsy (DRE) presents a significant challenge in managing epilepsy, affecting patient care and treatment success.
- Genetic factors, including variants in genes encoding drug targets and transporters, may contribute to DRE.
- Understanding genetic predispositions is crucial for improving epilepsy treatment strategies.
Purpose of the Study:
- To investigate the association between polymorphisms in SCN1A, GABRA1, and ABCB1 genes and drug response in Vietnamese children with epilepsy.
- To identify specific genetic variants that may serve as risk factors for drug-resistant epilepsy.
Main Methods:
- A cohort of 213 Vietnamese children with epilepsy (101 drug-responsive, 112 drug-resistant) was analyzed.
- Sanger sequencing was used to identify six single nucleotide polymorphisms (SNPs) in SCN1A, GABRA1, and ABCB1 genes.
- Statistical analyses (Chi-squared test, Fisher's exact test) were employed to correlate SNP genotypes with drug response status.
Main Results:
- Two out of six investigated SNPs showed a significant association with drug response.
- The heterozygous genotype of SCN1A rs2298771 (AG) was more frequent in drug-resistant epilepsy patients, indicating a risk factor.
- The heterozygous genotype of SCN1A rs3812718 (CT) was less frequent in drug-resistant patients compared to drug-responsive patients.
Conclusions:
- This study highlights a significant association between SCN1A genetic polymorphisms and an increased risk of drug-resistant epilepsy in Vietnamese children.
- These findings support the role of SCN1A gene variants in the pathogenesis of childhood drug-resistant epilepsy.
- Identifying these genetic markers could aid in predicting treatment outcomes and developing personalized epilepsy management strategies.
Abstract:
Background and Objectives: Drug resistant epilepsy (DRE) is a major hurdle in epilepsy, which hinders clinical care, patients' management and treatment outcomes. DRE may partially result from genetic variants that alter proteins responsible for drug targets and drug transporters in the brain. We aimed to examine the relationship between SCN1A, GABRA1 and ABCB1 polymorphism and drug response in epilepsy children in Vietnam. Materials and Methods: In total, 213 children diagnosed with epilepsy were recruited in this study (101 were drug responsive and 112 were drug resistant). Sanger sequencing had been performed in order to detect six single nucleotide polymorphisms (SNPs) belonging to SCN1A (rs2298771, rs3812718, rs10188577), GABRA1 (rs2279020) and ABCB1 (rs1128503, rs1045642) in study group. The link between SNPs and drug response status was examined by the Chi-squared test or the Fisher's exact test. Results: Among six investigated SNPs, two SNPs showed significant difference between the responsive and the resistant group. Among those, heterozygous genotype of SCN1A rs2298771 (AG) were at higher frequency in the resistant patients compared with responsive patients, playing as risk factor of refractory epilepsy. Conversely, the heterozygous genotype of SCN1A rs3812718 (CT) was significantly lower in the resistant compared with the responsive group. No significant association was found between the remaining four SNPs and drug response. Conclusions: Our study demonstrated a significant association between the SCN1A genetic polymorphism which increased risk of drug-resistant epilepsy in Vietnamese epileptic children. This important finding further supports the underlying molecular mechanisms of SCN1A genetic variants in the pathogenesis of drug-resistant epilepsy in children.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

